"This recent announcement further demonstrates the continued commitment by Jubilant Radiopharma to the sustainability and further advancement of nuclear medicine. Our goal is to grow the utilization of SPECT and PET technologies as part of our global commitment to reinvest into this industry and bring value to products and services that enable physicians to provide the best care for their patients every day," commented Douglas Gentilcore, vice president of Jubilant Radiopharma.

About Jubilant Pharma Limited Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectibles and nonaEURsterile products through five U.S. FDA-approved manufacturing facilities in the U.S., Canada and India and a network of over 50 radioaEURpharmacies in the U.S. The company has a team of over 4,300 multicultural people across the globe and is committed to delivering value to its customers spread across over 75 countries. It is well recognized as a "Partner of Choice" by leading pharmaceutical companies globally.

About Jubilant Radiopharma
Jubilant Radiopharma is an industry-leading radiopharmaceutical company focused on developing, manufacturing, commercializing and distributing high-quality and sustainable diagnostic and therapeutic agents for the sole purpose of Improving Lives Through Nuclear Medicine on a global scale.


SOURCE: Jubilant Radiopharma

Back to HCB News

Molecular Imaging Homepage